Image de couverture de livre

MRI‐Determined Tumor Contact Area as a Predictor of Pathological Extraprostatic Extension in Clinical T2 Prostate Cancer

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Masashi Tsujimoto, Yuta Inoue, Hideto Taga, Yumiko Saito, Masatomo Kaneko, Masatsugu Miyashita, Takeshi Yamada, Yasuhiro Yamada, Takashi Ueda, Atsuko Fujihara, Takumi Shiraishi, Masayoshi Okumi, Fumiya Hongo, Eiichi Konishi, Kaori Yamada, Kei Yamada, Osamu Ukimura
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Prostate Cancer
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Robot‐assisted radical cystectomy using real‐time transrectal ultrasound guidance in a patient who had radical prostatectomy and salvage external beam radiation therapy
par: Yuta Inoue, et autres
Publié: (2024)

Genitourinary malignancies in kidney transplant recipients
par: Masayoshi Okumi, et autres
Publié: (2024)

Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratification Scoring System
par: Toshifumi Takahashi, et autres
Publié: (2024)

Evaluation of Second‐Line Treatment for Castration‐Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors
par: Kazuro Kikkawa, et autres
Publié: (2024)

Percutaneous Cryoablation With Lipiodol Marking for Hereditary Renal Cell Carcinomas: Cancer Control and Renal Functional Outcomes
par: Shinya Miyazaki, et autres
Publié: (2025)

LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy
par: Sangjon Pae, et autres
Publié: (2025)

Significant Effect of Carbon‐Ion Radiation Therapy Combined With Androgen Deprivation on Biochemical Recurrence Rates in High‐Risk Prostate Cancer Patients: A Two‐Center Controlled Trial Compare With X‐Ray External Beam Radiation Therapy
par: Xue Zhao, et autres
Publié: (2024)

Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix
par: Shuhei Kamada, et autres
Publié: (2024)

Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features
par: Tatsuya Shimomura, et autres
Publié: (2026)

Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy
par: Shintaro Narita, et autres
Publié: (2024)

Prognostic Impact of Initial Prostate Specific Antigen Half‐Life After Abiraterone Acetate in High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: Who May Need Triplet Therapy?
par: Kotaro Suzuki, et autres
Publié: (2026)

A Two‐Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone‐Sensitive Prostate Cancer
par: Koichiro Kurokawa, et autres
Publié: (2026)

Evaluating Local Doses for Prostate Cancer Treatment Using Low‐Dose‐Rate Brachytherapy Considering Oncological Control and Toxicity
par: Yasushi Nakai, et autres
Publié: (2025)

Evaluation of Loss of the Y Chromosome in Peripheral Blood as a Biomarker for Prostate Cancer
par: Jun Lu, et autres
Publié: (2026)

Recurrence of seminoma 48 years after orchiectomy: Longest late recurrence and treatment
par: Shinya Miyazaki, et autres
Publié: (2025)

Diagnostic Performance of the Novel Biomarker S2,3PSA Density for Prostate Biopsy Optimization in Prostate Imaging Reporting and Data System 3–5 Lesions
par: Takanori Tokunaga, et autres
Publié: (2025)

Three‐dimensional ultrastructural and anatomical analysis of prostatic neuroendocrine cells in mice
par: Kei‐Ichiro Uemura, et autres
Publié: (2024)

Efficacy, Safety, and Cost‐Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer: A Multicenter Retrospective Study
par: Himawari Asanuma, et autres
Publié: (2026)

Refining the CHAARTED Classification: Clinical Utility of a Novel Integrated Risk Stratification Model Incorporating Gleason Grade and Biochemical Markers in Japanese Patients With Metastatic Hormone‐Sensitive Prostate Cancer
par: Takanori Tokunaga, et autres
Publié: (2025)

Other‐cause mortality in incidental prostate cancer
par: Francesco Di Bello, et autres
Publié: (2024)

Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy
par: Yuto Ono, et autres
Publié: (2025)

The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer
par: Cevat İlteriş Kıkılı, et autres
Publié: (2026)

Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors
par: Hyun‐Kyung Ko, et autres
Publié: (2025)

Cover Image: Volume 86 Issue 7
par: Amod Sharma, et autres
Publié: (2026)

External validation of the Memorial Sloan Kettering Cancer Center preoperative nomogram predicting lymph node invasion in a cohort of high‐grade prostate cancer patients
par: Nawar Touma, et autres
Publié: (2024)

Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate
par: Eric V. Li, et autres
Publié: (2024)

Discovering the Prostate: Notes on History and Historiography
par: Diederik F. Janssen
Publié: (2025)

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer
par: Fabian Falkenbach, et autres
Publié: (2025)

Insights and Limitations in Evaluating Testosterone Recovery With LHRH Antagonists and Agonists
par: Satı Coşkun Yazgan, et autres
Publié: (2026)

Real‐World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: A Propensity‐Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis
par: Yosuke Yasuda, et autres
Publié: (2026)

Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease
par: Mark Kidd, et autres
Publié: (2025)

Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience
par: Meryam Losee, et autres
Publié: (2025)

Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer
par: Hirotaka Nagasaka, et autres
Publié: (2024)

Individualized Precision Prostate Biopsy Strategy for Patients With PI‐RADS Score 2: A Retrospective Multicenter Study
par: Zhiyao Xu, et autres
Publié: (2025)

Integration of Primary Care Into the Follow‐Up Protocol for Prostate Cancer Patients in Aragon, Spain. It Is Time to Follow Other Successful Models in the Region
par: Angel Borque‐Fernando, et autres
Publié: (2025)

Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes
par: Christian P. Pavlovich, et autres
Publié: (2025)

Use of Droplet Digital PCR for Consistent Detection of TMPRSS2:ERG Gene Fusion Transcripts Initiated In Vitro
par: Megan H. Check, et autres
Publié: (2025)

Challenging the Evolving Nomenclature of Ultrasound‐Guided Transperineal Prostate Biopsy: A Call for Standardization
par: Pedro Ivo C. Ravizzini, et autres
Publié: (2026)

Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer
par: Umang Swami, et autres
Publié: (2024)

Correction to “[Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study ( The Prostate , 2025). https://doi.org/10.1002/pros.70071]”
Publié: (2026)